{
    "clinical_study": {
        "@rank": "167990", 
        "acronym": "BoneGlyc", 
        "arm_group": [
            {
                "arm_group_label": "Vildagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Vildagliptin 50 mg bid for 12 months"
            }, 
            {
                "arm_group_label": "Gliclazide MR", 
                "arm_group_type": "Active Comparator", 
                "description": "Gliclazide MR 60 or 120mg once a day for 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Monocentric, Prospective, Randomized, Open-label, Comparative, Phase IV Study, to\n      compare the effects of Vildagliptin and Gliclazide MR on Markers of Bone Remodeling, Bone\n      Mineral Density and Glycemic Variability in Postmenopausal Women with Type 2 Diabetes.\n\n      A total of 38 women with documented Type 2 Diabetes and menopause will be enrolled. The\n      active treatment will include a 50 mg dose of vildagliptin OD twice a day. As comparator,\n      gliclazide MR will be administered at a dose of 60 to 120 mg OD once a day."
        }, 
        "brief_title": "Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes Mellitus", 
            "Menopause", 
            "Osteoporosis", 
            "Osteopenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Bone Diseases, Metabolic", 
                "Osteoporosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Monocentric, Prospective, Randomized, Open-label, Comparative, Phase IV Study, to\n      compare the effects of Vildagliptin and Gliclazide MR on Markers of Bone Remodeling, Bone\n      Mineral Density and Glycemic Variability in Postmenopausal Women with Type 2 Diabetes.\n\n      Target population of clinical trial subjects A total of 38 women with documented Type 2\n      Diabetes and menopause will be enrolled. To be as close to a real life scenario as possible,\n      clinical trial subjects which are treated with glucose-lowering medication (except incretin\n      or sulfonylurea based therapies) and treatment-naive subjects will be included.\n\n      Investigational Product, posology and method of administration The active treatment will\n      include a 50 mg dose of vildagliptin OD twice a day.\n\n      Comparator, posology and method of administration As comparator, gliclazide MR will be\n      administered at a dose of 60 to 120 mg OD once a day.\n\n      Treatment duration The study will have an expected total duration of 18 months, 12 months of\n      active treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent form obtained before any study-related activity. Study-related\n             activities are any procedure that would not be performed during the normal treatment\n             of the patient.\n\n          -  All study subjects must be women diagnosed with type 2 diabetes based on current\n             guidelines of Sociedade Brasileira de Diabetes (SBD - Brazilian Society of Diabetes)\n             and/or American Society of Diabetes (ADA) and they should have all the following\n             criteria:\n\n               -  Age \u2265 40 years old.\n\n               -  HbA1c \u2265 6.5% at randomization.\n\n          -  Menopause defined as:\n\n          -  Absence of menstruation for at least 12 months in patients with an intact uterus, or\n\n          -  FSH level greater than 30 mIU/mL in a hysterectomized patient and/or,\n\n          -  FSH level greater than 30 mIU/mL in a patient with surgical menopause.\n\n        Exclusion Criteria:\n\n          -  Acute vascular event (cardiac, cerebral or peripheral) for at least 2 months of\n             randomization.\n\n          -  Patient on chronic dialysis and/or renal transplantation and/or serum creatinine >\n             1.5 mg/dL.\n\n          -  Patients with HIV, severe autoimmune disease or chronic treatment with oral steroids\n             (> 30 consecutive days).\n\n          -  Current or previous treatment (within 6 months) with incretin (DPP-IV inhibitor or\n             GLP-1 analog) within 6 months prior to randomization.\n\n          -  Current or previous treatment with pioglitazone or rosiglitazone within 12 months\n             prior to randomization.\n\n          -  Sustained arterial hypertension > 180/100 mm Hg.\n\n          -  Body mass index (BMI) > 50 kg/m\u00b2.\n\n          -  HbA1c \u2265 9,5% at randomization.\n\n          -  Transaminases (AST (SGOT) and ALT (SGPT)) > 2.5 x upper limit of normal.\n\n          -  Chronic liver disease or alcoholic liver disease.\n\n          -  LDL-cholesterol > 250 mg/dL (> 6.48 mmol/L).\n\n          -  Triglycerides > 1000 mg/dL (> 11.3 mmol/L).\n\n          -  HDL-cholesterol < 25 mg/dL (< 0.64 mmol/L).\n\n          -  Levels of 25-OH-vitamin D < 20ng/mL at randomization\n\n          -  Abnormal levels of PTH, cortisol, IGF-1 or GH at randomization\n\n          -  Prescription of any investigational medication within one year before the screening\n             visit (visit 1), unless there is a direct benefit to the study subject, at the\n             discretion of the investigator.\n\n          -  History of previous fracture\n\n          -  Pregnant or breastfeeding patients.\n\n          -  Previous participation on this study.\n\n          -  Individuals at risk for poor adherence to the protocol or medication.\n\n          -  Any condition that makes the patient unable to complete the study within 12 months."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679899", 
            "org_study_id": "BoneGlyc"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vildagliptin", 
                "description": "Vildagliptin 50mg bid orally for 12 months", 
                "intervention_name": "Vildagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Galvus"
            }, 
            {
                "arm_group_label": "Gliclazide MR", 
                "description": "Gliclazide MR 60 or 120mg orally for 12 months", 
                "intervention_name": "Gliclazide MR", 
                "intervention_type": "Drug", 
                "other_name": "Diamicron MR"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vildagliptin", 
                "Gliclazide", 
                "Hypoglycemic Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes", 
            "type 2 diabetes mellitus", 
            "osteopenia", 
            "osteoporosis", 
            "glycemic variability", 
            "bone markers", 
            "osteocalcin", 
            "NTX", 
            "CTX", 
            "BALP"
        ], 
        "lastchanged_date": "July 15, 2013", 
        "location": {
            "contact": {
                "email": "pesquisaclinica_mari@yahoo.com.br", 
                "last_name": "Marinez Jucovski, Coordinator", 
                "phone": "+55(41)92368794"
            }, 
            "facility": {
                "address": {
                    "city": "Curitiba", 
                    "country": "Brazil", 
                    "state": "Parana", 
                    "zip": "80810040"
                }, 
                "name": "Centro de Diabetes Curitiba"
            }, 
            "investigator": [
                {
                    "last_name": "Andre GD Vianna, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Claudio S Lacerda, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Luciana M Pechmann, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andressa M Leitao, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Edgard D Niclewicz, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR", 
        "other_outcome": {
            "description": "Dosage of alanine aminotransferase (ALT, SGOT) and aspartate aminotransferase (AST, SGPT)", 
            "measure": "Levels of aminotransferases", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "overall_contact": {
            "email": "vianna.a@uol.com.br", 
            "last_name": "Andre GD Vianna, MD", 
            "phone": "+55(41)30231252"
        }, 
        "overall_contact_backup": {
            "email": "edgardniclewicz@terra.com.br", 
            "last_name": "Edgard Niclewicz, MD", 
            "phone": "+55(41)30231252"
        }, 
        "overall_official": {
            "affiliation": "Centro de Diabetes Curitiba", 
            "last_name": "Andre GD Vianna, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary outcome is to compare the effect of vildagliptin with gliclazide MR on markers of bone remodeling. The outcome variables are the blood levels of:\nOsteocalcin (OC)\nBone-specific alkaline phosphatase (BALP)\nCarboxy-terminal telopeptide of type I collagen (CTX)\nAmino-terminal telopeptide of type I collagen (NTX)", 
            "measure": "Markers of bone remodeling", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the effect of vildagliptin with gliclazide MR on bone mineral density of lumbar spine and femur by X-ray absorptiometry after 12-month treatment.", 
                "measure": "Bone mineral density of lumbar spine and femur by X-ray absorptiometry", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To compare the effect of vildagliptin with gliclazide MR on glycemic variability measured by MAGE method (mean amplitude of glycemic excursion) using a continuous glucose monitoring system", 
                "measure": "Glycemic variability", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Dosage of serum calcitonin", 
                "measure": "Calcitonin", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Centro de Diabetes Curitiba Ltda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centro de Diabetes Curitiba Ltda", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}